Tobacco dependence is prevalent in patients with opioid abuse histories. Cigarette smoking rates in both intreatment and out-of-treatment samples generally range from 80 to 90%. There have been few attempts to treat opioid dependent smokers, and the extant attempts have met with limited success. The proposed study is an attempt to use an innovative motivational system, combined with extended behavioral and pharmacological treatment, to produce sustained abstinence in this population. The intervention is modeled on those used successfully in published and on-going work by our group with other complex smokers. The primary hypothesis is that the Innovative System (IS) will be more effective than the Standard Treatment Control (STC) at 12 and 18 months after entrance into the intervention. Hypotheses concerning individual differences in outcomes are also proposed, and these include both behavioral and pharmacogenetic variables. The data will also provide preliminary information about whether smoking cessation or cessation attempts are correlated with change in use of illicit drugs. Two-hundred buprenorphine treatment patients who smoke more than five cigarettes per day will be randomly assigned to either IS or to STC. Intent to quit smoking is not required as an inclusion criterion. In the STC, participants will receive a brochure on quitting, a list of local referrals, and an information sheet that tells them how to obtain cessation medication through the City of San Francisco public health care system. In the IS, participants will be counseled using a computerized counseling system at baseline and months 3, 6, and 12. The system is designed to increase motivation to quit smoking. At any time after entrance into the study up until month 12, if the participant requests smoking cessation treatment, treatment that uses both combined pharmacotherapy and behavioral counseling will be provided. Pharmacotherapy will consist of nicotine replacement treatment (NRT). If NRT fails to produce abstinence, varenicline will be provided. Treatment is available for six months after it is initiated. Assessment points are at baseline, and months 3, 6, 12, and 18. Seven-day point prevalence abstinence from cigarettes is the primary dependent variable. This study is significant in that it offers an innovative approach for a population with high smoking rates.

Public Health Relevance

This project compares an innovative intervention for tobacco dependence with standard treatment for cigarette smokers who are also being treated for opioid dependence. If successful, this intervention will improve the health of opioid addicted individuals. There is a high rate of smoking in this population, and current treatments have had limited success. Thus, it will contribute to the public health by decreasing the use of a harmful substance?tobacco?in one group of smokers.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA009253-18
Application #
8376908
Study Section
Special Emphasis Panel (ZDA1-EXL-T)
Project Start
2012-06-01
Project End
2015-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
18
Fiscal Year
2012
Total Cost
$468,519
Indirect Cost
$163,677
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Guydish, Joseph; Le, Thao; Campbell, Barbara et al. (2017) Drug abuse staff and clients smoking together: A shared addiction. J Subst Abuse Treat 76:64-68
Gubner, Noah R; Guydish, Joseph; Humfleet, Gary L et al. (2017) Nicotine biomarkers and rate of nicotine metabolism among cigarette smokers taking buprenorphine for opioid dependency. Drug Alcohol Depend 178:267-270
Das, Smita; Hickman, Norval J; Prochaska, Judith J (2017) Treating Smoking in Adults With Co-occurring Acute Psychiatric and Addictive Disorders. J Addict Med 11:273-279
Flentje, Annesa; Shumway, Martha; Wong, Lauren H et al. (2017) Psychiatric Risk in Unstably Housed Sexual Minority Women: Relationship between Sexual and Racial Minority Status and Human Immunodeficiency Virus and Psychiatric Diagnoses. Womens Health Issues 27:294-301
Murray, Donna E; Durazzo, Timothy C; Schmidt, Thomas P et al. (2017) Regional cerebral blood flow in opiate dependence relates to substance use and neuropsychological performance. Addict Biol :
Storholm, Erik D; Volk, Jonathan E; Marcus, Julia L et al. (2017) Risk Perception, Sexual Behaviors, and PrEP Adherence Among Substance-Using Men Who Have Sex with Men: a Qualitative Study. Prev Sci 18:737-747
Guydish, Joseph; Yip, Deborah; Le, Thao et al. (2017) Smoking-related outcomes and associations with tobacco-free policy in addiction treatment, 2015-2016. Drug Alcohol Depend 179:355-361
Thrul, Johannes; Ramo, Danielle E (2017) Cessation Strategies Young Adult Smokers Use After Participating in a Facebook Intervention. Subst Use Misuse 52:259-264
Guydish, Joseph; Tajima, Barbara; Pramod, Sowmya et al. (2016) Use of multiple tobacco products in a national sample of persons enrolled in addiction treatment. Drug Alcohol Depend 166:93-9
Murray, Donna E; Durazzo, Timothy C; Schmidt, Thomas P et al. (2016) Frontal Metabolite Concentration Deficits in Opiate Dependence Relate to Substance Use, Cognition, and Self-Regulation. J Addict Res Ther 7:

Showing the most recent 10 out of 324 publications